Funded Clinical Trial: Novel Probiotic Therapy for Canine Chronic Enteropathy

Nov 17, 2020 / Practitioner Updates

Idiopathic chronic enteropathies, includ­ing inflammatory bowel diseases, are common in dogs. Current therapies, in­cluding dietary modification, antibiotics, and glucocorticoids may be ineffective or may bring about adverse side effects.

Therapies that modify the gastroin­testinal microbiome offer a promising alternative to existing treatments. Probi­otics contain living microorganisms that confer health benefits or treat disease in the host animal.

We are conducting a double-blinded, randomized, placebo-controlled clinical trial to evaluate a new probiotic contain­ing three bacteria that reduce intestinal inflammation and promote intestinal healing as a treatment for chronic enteropathies in dogs.

Eligibility Criteria:

  • Dogs >1 year of age with signs of gastro­intestinal dysfunc­tion lasting ≥ 3 weeks
  • Free of enteric parasites and no systemic diseases based on a CBC and serum chemistry panel
  • One or more of the following: Diar­rhea, vomiting, weight loss, changes in appetite

Study Design:

Enrolled dogs will be randomly assigned to receive either the probiotic powder or a placebo. After 30 days, dogs in the placebo group will be switched into the probiotic group so that all dogs enrolled in the trial will have the opportunity to receive the probiotic supplement.

For more information, visit: go.illinois.edu/ProbioticClinicalTrial20-21

To contact the investigators, call: 217-300-9872 or email: probiotic-trial@vetmed.illinois.edu.